Oddo BHF Asset Management Sas Has $12.88 Million Stake in AbbVie Inc. $ABBV

Oddo BHF Asset Management Sas raised its stake in AbbVie Inc. (NYSE:ABBV) by 3.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 59,211 shares of the company’s stock after acquiring an additional 2,144 shares during the quarter. Oddo BHF Asset Management Sas’ holdings in AbbVie were worth $12,878,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Bank of Jackson Hole Trust lifted its stake in AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares during the last quarter. Eclectic Associates Inc. ADV grew its stake in shares of AbbVie by 0.8% during the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after buying an additional 45 shares during the last quarter. Imprint Wealth LLC grew its stake in shares of AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares during the last quarter. Dogwood Wealth Management LLC increased its holdings in shares of AbbVie by 10.8% during the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after buying an additional 46 shares in the last quarter. Finally, Quantum Private Wealth LLC increased its holdings in shares of AbbVie by 2.0% during the fourth quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock worth $543,000 after buying an additional 46 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $263.58 on Thursday. AbbVie Inc. has a 52 week low of $187.62 and a 52 week high of $267.47. The firm has a market cap of $465.69 billion, a PE ratio of 129.84, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30. The firm’s fifty day moving average is $237.54 and its 200-day moving average is $223.60.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.46 earnings per share. Sell-side analysts forecast that AbbVie Inc. will post 14.14 EPS for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is 340.89%.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price objective on AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Citigroup increased their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. UBS Group lifted their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Finally, DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $269.29.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Union approved RINVOQ for adults and adolescents aged 12 and older with severe alopecia areata. The decision was supported by Phase 3 data showing statistically significant scalp, eyebrow and eyelash hair regrowth, including complete scalp regrowth for some patients. RINVOQ alopecia areata approval
• Positive Sentiment: RINVOQ also received EU approval for non-segmental vitiligo in patients 12 and older who are candidates for systemic therapy. AbbVie described it as the first and only systemic treatment approved in the EU for this condition, creating another potential revenue opportunity for the drug. RINVOQ vitiligo approval
• Positive Sentiment: The approvals reinforce investor expectations that RINVOQ and Skyrizi can continue replacing Humira as AbbVie’s primary growth engines. The two drugs have been highlighted as key drivers ahead of earnings, while AbbVie’s long dividend-raise record supports its appeal to income-focused investors.
• Positive Sentiment: Unusual options activity showed investors purchasing approximately 19,745 call contracts, about 18% above average call volume. This indicates increased bullish positioning, although options activity is not a guarantee of future performance.
• Neutral Sentiment: Erste Group raised its 2027 EPS forecast for AbbVie to $16.40 from $16.27 but slightly lowered its 2026 estimate to $14.05 from $14.08, leaving the near-term earnings outlook mixed.
• Negative Sentiment: After a strong multiyear rally, valuation concerns and the possibility of “sell the news” volatility could limit further gains, particularly if second-quarter results or guidance do not exceed elevated expectations.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.